LogoLogo
Illumina KnowledgeIllumina SupportSign In
  • Home
  • Overview
    • Welcome
    • What's New
      • Cloud Software Update
      • Local Software Update
  • Configure
    • Configuration
      • Custom Case Data
      • Pipeline and QC Configuration
      • Preferred Transcripts
      • Custom Annotations
      • Disease Configuration
      • Variant Filters
      • Variant Flag Groups
      • Actionability Classifications
      • Report Templates
        • Customizations
      • Report Automation
      • Test Definitions
      • Data Upload
        • Data Upload from User Storage (Connected Insights - Cloud and Connected Insights - Local)
        • Data Upload from ICA or BSSH (Connected Insights - Cloud)
        • Supported Pipelines
          • DRAGEN TruSight Oncology 500 Analysis Software v2.6.0 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.6.0
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.3 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.3
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.2 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.5.2
          • DRAGEN TruSight Oncology 500 Analysis Software v2.1.1 (with HRD)
          • DRAGEN TruSight Oncology 500 Analysis Software v2.1.1
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.6.1
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.6.0
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.5.0
          • DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.1.1
          • DRAGEN Amplicon v4.3
          • DRAGEN Amplicon v4.2
          • DRAGEN Amplicon v4.1
          • DRAGEN RNA v4.3
          • DRAGEN RNA v4.2
          • DRAGEN RNA v4.1
          • DRAGEN Enrichment v4.3
          • DRAGEN Enrichment v4.2
          • DRAGEN Enrichment v4.1
          • DRAGEN for Illumina cfDNA Prep with Enrichment v4.0.3
          • DRAGEN Somatic Whole Genome v4.3
          • DRAGEN Somatic Whole Genome v4.2
          • DRAGEN Somatic Whole Genome v4.1
          • TruSight Tumor 170 Local App v2.0.1
          • Local Run Manager TruSight Tumor 15 Analysis Module v2.1
        • Custom Pipeline Configuration
          • VCF Input Requirement
          • TMB, MSI, GIS Input Requirement
        • Custom Case Data Upload
    • Upload Assertions
    • Local Installation Guide
      • Overview
      • Prerequisites
      • Download Connected Insights Package
      • Install Connected Insights Software
      • Install License File
      • Sign In to Connected Insights
      • Installation Status Messages
      • Local Configurations
      • Administration Console (Connected Insights - Local)
      • Configure External Storage (Connected Insights - Local)
  • Manage cases
    • Cases Page
    • Cases List
      • Case Metadata Upload
  • Interpret and report
    • Case Page
    • Case Details
      • Merge Cases
    • Overview Tab
      • Classification & Risk Stratification Prediction
    • Visualize Tab
    • Variants Tab
      • Modify Columns
      • Apply Variant Filters
        • Filter by Variant Category
        • Variant Details Filters
        • Variant Quality Filters
        • Functional Impact Filters
        • Disease Association Filters
        • Variant Frequency Filters
        • Flags Filter
        • Filtering Logic
      • IGV Visualizations
    • Lab QC Tab
    • Report Tab
    • View Biomarker Details
      • Biological Classification
      • Actionability
      • Clinical Trials
      • Oncogenicity Prediction
      • Visualize
      • Variant Overview
      • Gene Overview
      • Cancer Datasets
      • Computer Predictors
      • Population
    • Interpret a Biomarker
      • Create Clinical Trials
      • Create Gene Descriptions
      • Manage Assertions
    • Variant Transcripts
    • Add Variant
  • Resources and References
    • Glossary
    • APIs
      • Ingest Cloud Analysis Data API (Connected Insights - Cloud Only)
      • Case APIs
      • Report APIs
      • Audit Log APIs
    • Troubleshooting
      • Overview
      • Audit Log
      • Data Backup (Connected Insights - Local)
      • Software Errors and Corrective Actions
      • How To
      • Technical Assistance
    • Pricing and Usage
    • Security and Compliance
    • Release Notes
Powered by GitBook
On this page
  • Overview
  • Reporting
  • Decision Trees
  • APL with PML::RARA fusion
  • AML with RUNX1::RUNX1T1 fusion
  • AML with CBFB::MYH11 fusion
  • AML with DEK::NUP214 fusion
  • AML with RBM15::MRTFA fusion
  • AML with BCR::ABL1 fusion
  • AML with KMT2A rearrangement
  • AML with MECOM rearrangement
  • AML with NUP98 rearrangement
  • AML with NPM1 mutation
  • AML with CEBPA mutation
  • AML with other defined genetic alterations
  • AML, myelodysplasia-related
  • Definitions

Was this helpful?

Export as PDF
  1. Interpret and report
  2. Overview Tab

Classification & Risk Stratification Prediction

PreviousOverview TabNextVisualize Tab

Last updated 4 months ago

Was this helpful?

Classification & Risk Stratification Prediction is available for cases created using Connected Insights v5.1+.

Overview

If the case disease is Acute Myeloid Leukemia or a subtype, Classification & Risk Stratification Prediction is provided on the Overview Tab.

Reporting

The report interpretation summary can be generated from the prediction results by clicking Report.

Decision Trees

All variants described below must pass secondary analysis filters (VCF Filter = PASS).


APL with PML::RARA fusion

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of PML::RARA fusion in the Variants Tab

    • Detection of t(15;17)(q24;q21) in the User Determined Karyotype

If the above is met, the classification is predicted to be APL with PML::RARA fusion.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


AML with RUNX1::RUNX1T1 fusion

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of RUNX1::RUNX1T1 fusion in the Variants Tab

    • Detection of t(8;21)(q21.3;q22.1) in the User Determined Karyotype

The guideline specifies an outdated band 8q22 for RUNX1T1. It is now 8q21.3.

If the above is met, the classification is predicted to be AML with RUNX1::RUNX1T1 fusion.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then Favorable.


AML with CBFB::MYH11 fusion

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of CBFB::MYH11 fusion in the Variants Tab

    • Detection of inv(16)(p13.1q22.1) in the User Determined Karyotype

    • Detection of t(16;16)(p13.1;q22.1) in the User Determined Karyotype

If the above is met, the classification is predicted to be AML with CBFB::MYH11 fusion.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then Favorable.


AML with DEK::NUP214 fusion

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of DEK::NUP214 fusion in the Variants Tab

    • Detection of t(6;9)(p22.3;q34.1) in the User Determined Karyotype

If the above is met, the classification is predicted to be AML with DEK::NUP214 fusion.

Risk Stratification

Adverse


AML with RBM15::MRTFA fusion

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of RBM15::MRTFA fusion in the Variants Tab

    • Detection of t(1;22)(p13.3;q13.1) in the User Determined Karyotype

If the above is met, the classification is predicted to be AML with RBM15::MRTFA fusion.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


AML with BCR::ABL1 fusion

Classification

  • Blast count % ≥ 20

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of BCR::ABL1 fusion in the Variants Tab

    • Detection of t(9;22)(q34.1;q11.2) in the User Determined Karyotype

If the above is met, the classification is predicted to be AML with BCR::ABL1 fusion.

Risk Stratification

Adverse


AML with KMT2A rearrangement

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Detection of KMT2A structural variant in the Variants Tab

If the above is met, the classification is predicted to be AML with KMT2A rearrangement.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

  • Any of the following:

    • Detection of MLLT3::KMT2A in the Variants Tab

    • Detection of t(9;11)(p21.3;q23.3) in the User Determined Karyotype

    • Detection of KMT2A partial tandem duplication in the Variants Tab

If the above is met, the risk stratification is predicted to be Intermediate. If not, then Adverse.


AML with MECOM rearrangement

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of MECOM structural variant in the Variants Tab

    • Detection of inv(3)(q21.3q26.2) in the User Determined Karyotype

    • Detection of t(3;3)(q21;q26) in the User Determined Karyotype

    • Detection of t(3;21)(q26.2;q22) in the User Determined Karyotype

    • Detection of t(3;12)(q26.2;p13) in the User Determined Karyotype

If the above is met, the classification is predicted to be AML with MECOM rearragement.

Risk Stratification

Adverse


AML with NUP98 rearrangement

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of NUP98 structural variant in the Variants Tab

    • Detection of t(5;11)(q35.2;p15.4) in the User Determined Karyotype

    • Detection of t(11;12)(p15.4;p13.3) in the User Determined Karyotype

If the above is met, the classification is predicted to be AML with NUP98 rearrangement.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


AML with NPM1 mutation

Classification

  • Blast count % ≥ 10

  • History of cytotoxic therapy exposure = No

  • Detection of NPM1 variant in the Variants Tab with the following characteristics:

    • Small variant

If the above is met, the classification is predicted to be AML with NPM1 mutation.

Risk Stratification

  • Any of the following:

    • Detection of TP53 variant in the Variants Tab with the following characteristics:

      • Small variant

      • Somatic origin (origin = somatic or unknown)

      • Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or oncogenicity prediction)

      • VAF ≥ 0.10 (10%)

    • Detection of DEK::NUP214 fusion in the Variants Tab

    • Detection of t(6;9)(p22.3;q34.1) in the User Determined Karyotype

    • Detection of KMT2A structural variant without MLLT3 fusion partner in the Variants Tab

    • Detection of BCR::ABL1 fusion in the Variants Tab

    • Detection of t(9;22)(q34.1;q11.2) in the User Determined Karyotype

    • Detection of KAT6A::CREBBP fusion in the Variants Tab

    • Detection of t(8;16)(p11.2;p13.3) in the User Determined Karyotype

    • Detection of MECOM structural variant in the Variants Tab

    • Detection of inv(3)(q21.3q26.2) in the User Determined Karyotype

    • Detection of t(3;3)(q21;q26) in the User Determined Karyotype

    • Detection of t(3;21)(q26.2;q22) in the User Determined Karyotype

    • Detection of t(3;12)(q26.2;p13) in the User Determined Karyotype

    • Detection of monosomy 5 in the User Determined Karyotype or Variants Tab

    • Detection of 5q deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

    • Detection of monosomy 7 in the User Determined Karyotype or Variants Tab

    • Detection of monosomy 17 in the User Determined Karyotype or Variants Tab

    • Detection of 17p deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

  • Detection of FLT3 internal tandem duplication in the Variants Tab

If the above is met, the risk stratification is predicted to be Intermediate. If not, then Favorable.


AML with CEBPA mutation

Classification

  • None of the classifications above should be met.

  • Blast count % ≥ 20

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of 2 CEBPA variants in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of CEBPA variant in the Variants Tab with the following characteristics:

      • Small variant

      • Located in the bZIP domain

The guideline requires biallelic mutations, whereas the evaluation simply checks for 2 due to lack of cis/trans information.

If the above is met, the classification is predicted to be AML with CEBPA mutation.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

  • Detection of CEBPA variant in the Variants Tab with the following characteristics:

    • Small variant

    • In-frame (not a frameshift variant)

If the above is met, the risk stratification is predicted to be Favorable. If not, then Intermediate.


AML with other defined genetic alterations

Classification

  • None of the classifications above should be met.

  • Blast count % ≥ 20

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • Detection of CBFA2T3::GLIS2 fusion in the Variants Tab

    • Detection of inv(16)(p13q24) in the User Determined Karyotype

    • Detection of KAT6A::CREBBP fusion in the Variants Tab

    • Detection of t(8;16)(p11.2;p13.3) in the User Determined Karyotype

    • Detection of FUS::ERG fusion in the Variants Tab

    • Detection of t(16;21)(p11;q22) in the User Determined Karyotype

    • Detection of MNX1::ETV6 fusion in the Variants Tab

    • Detection of t(7;12)(q36;p13) in the User Determined Karyotype

    • Detection of NPM1::MLF1 fusion in the Variants Tab

    • Detection of t(3;5)(q25;q35) in the User Determined Karyotype

If the above is met, the classification is predicted to be AML with other defined genetic alterations.

Risk Stratification

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

  • Any of the following:

    • Detection of KAT6A::CREBBP fusion in the Variants Tab

    • Detection of t(8;16)(p11.2;p13.3) in the User Determined Karyotype

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


AML, myelodysplasia-related

Classification

  • None of the classifications above should be met.

  • Blast count % ≥ 20

  • History of cytotoxic therapy exposure = No

  • Any of the following:

    • History of myelodysplastic syndrome = Yes

    • Both of the following:

      • History of myelodysplastic syndrome = Yes

      • History of myeloproliferative neoplasm = Yes

    • Detection of 5q deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

    • Detection of monosomy 7 in the User Determined Karyotype or Variants Tab

    • Detection of 11q deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

    • Detection of 12p deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

    • Detection of monosomy 13 in the User Determined Karyotype or Variants Tab

    • Detection of 17p deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

    • Detection of isochromosome 17q in the User Determined Karyotype

    • Detection of idic(X)(q13) in the User Determined Karyotype

    • Detection of ASXL1 variant in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of BCOR variant in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of EZH2 variant in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of SF3B1 variant in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of SRSF2 variant in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of STAG2 variant in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of U2AF1 variant in the Variants Tab with the following characteristics:

      • Small variant

    • Detection of ZRSR2 variant in the Variants Tab with the following characteristics:

      • Small variant

If the above is met, the classification is predicted to be AML, myelodysplasia-related.

Risk Stratification

Any of the following:

  • Detection of TP53 variant in the Variants Tab with the following characteristics:

    • Small variant

    • Somatic origin (origin = somatic or unknown)

    • VAF ≥ 0.10 (10%)

  • Detection of monosomy 5 in the User Determined Karyotype or Variants Tab

  • Detection of 5q deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

  • Detection of monosomy 7 in the User Determined Karyotype or Variants Tab

  • Detection of monosomy 17 in the User Determined Karyotype or Variants Tab

  • Detection of 17p deletion in the User Determined Karyotype, or Variants Tab with length ≥ 5 Mbp

  • Detection of ASXL1 variant in the Variants Tab with the following characteristics:

    • Small variant

  • Detection of BCOR variant in the Variants Tab with the following characteristics:

    • Small variant

  • Detection of EZH2 variant in the Variants Tab with the following characteristics:

    • Small variant

  • Detection of SF3B1 variant in the Variants Tab with the following characteristics:

    • Small variant

  • Detection of SRSF2 variant in the Variants Tab with the following characteristics:

    • Small variant

  • Detection of STAG2 variant in the Variants Tab with the following characteristics:

    • Small variant

  • Detection of U2AF1 variant in the Variants Tab with the following characteristics:

    • Small variant

  • Detection of ZRSR2 variant in the Variants Tab with the following characteristics:

    • Small variant

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


Definitions

Complex Karyotype

According to WHO/ISCN: ≥ 3 abnormalities, where abnormalities are counted as follows:

  • Only clonal abnormalities are counted; abnormalities present in only 1 metaphase are ignored.

  • Numerical gains and losses, simple and complex balanced translocations, unbalanced aberrations involving one chromosome, as well as multiplication of a complete chromosome set are counted as one abnormality.

  • Unbalanced aberrations involving two or more chromosomes, tetrasomy of same chromosome, triplication or quadruplication, as well as isoderivative chromosomes, are counted as 2 abnormalities.

  • Constitutional abnormalities are not counted.

  • In case of multiple clones (subclones or independent clones), chromosome abnormalities in each clone/subclone are counted separately and the number of chromosomal abnormalities is defined by the clone with the highest abnormalities.

  • For composite karyotypes, clonal chromosomal aberrations are counted in metaphases with the highest number of abnormalities.

Monosomal Karyotype

According to ELN: Presence of two or more distinct monosomies (excluding loss of X or Y), or one single autosomal monosomy in combination with at least one structural chromosome abnormality.

Classification and risk stratification predictions are based on and acute myeloid leukemia guidelines, respectively, focusing on Acute myeloid leukemia with defining genetic abnormalities.

Select a box to review how the evaluation was performed. For more information, refer to below.

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Detection of in the User Determined Karyotype or Variants Tab

Detection of in the User Determined Karyotype or Variants Tab

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Detection of in the User Determined Karyotype or Variants Tab

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Detection of in the User Determined Karyotype or Variants Tab

Detection of in the User Determined Karyotype or Variants Tab

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

Oncogenic or likely oncogenic (as indicated by a knowledge base biological classification or )

WHO 2022
ELN 2022
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
oncogenicity prediction
Decision Trees
complex karyotype
monosomal karyotype
complex karyotype
complex karyotype
monosomal karyotype
APL with PML::RARA fusion prediction with decision tree
Generated interpretation summary text